Hints and tips:
...Peter Bach, director of the Center for Health Policy and Outcomes at the Memorial Sloan-Kettering cancer centre, said even if the cost of raw materials was rising, this was usually a low proportion of the...
...data that can be integrated with data from its current services to entrench its monopoly power,” said groups including the Open Markets Institute, Public Citizen and the Electronic Privacy Information Center...
...David Friend, co-founder of the BDO Center for Healthcare Excellence and Innovation, said the hearing will be “political theatre”....
...“These clinical data now suggest this combination as a new standard of care for the first-line treatment of these . . . patients,” said Dr Leena Gandhi, an oncologist at the NYU Langone Medical Center, who...
...For decades, the field of cancer immunotherapy was dismissed as a dead-end by most drugmakers until the remarkable success of “checkpoint inhibitor” drugs, such as Merck’s Keytruda and Bristol-Myers Squibb...
...Lines of battered RVs line certain streets in places such as Mountain View, where the courts have said they can park for 72 hours at a time....
...“Some people that get just one dose have a high likelihood of responding,” said Dr Michael Postow, an oncologist at the Memorial Sloan Kettering Cancer Center in New York....
...The first of these so-called immunotherapies was launched by Merck and Bristol-Myers Squibb last year and analysts expect them to generate $35bn of annual sales within a decade....
...However, Peter Bach, a physician and director at the Memorial Sloan-Kettering Cancer Center in New York, warned that the high prices risked “heaping an economic catastrophe on to a health catastrophe”....
...Two of the first immunotherapies — Keytruda from Merck & Co and Opdivo from Bristol-Myers Squibb — were approved by US regulators last year, each carrying a price tag of $150,000 per patient, per year....
...The book, written by Heidi Grant Halvorson and Tory Higgins from Columbia Business School’s Motivation Science Center, draws on social psychology and explores how to identify, change and use focus to get...
...The news dealt a blow to Mead Johnson, which was split off from Bristol-Myers Squibb in 2009, but Ken Goldman, analyst at JPMorgan, said that it was too soon to tell if investors were overreacting to the...
...Research continued, but in 1977 it received a fillip in the form of a desperate plea from the National Cardiovascular Center in Osaka....
...Rent-A-Center shares were up 3.8 per cent, or $1.02, at $28.01....
...One factor influencing his decision, he said, was a lawsuit filed in Germany by the US-based Center for Constitutional Rights accusing him of war crimes over Abu Ghraib....
...But in contrast to the Japanese acquisitions of New York’s Rockefeller Center, the Pebble Beach golf course and Hollywood film studios, Chinese companies seem unwilling to overpay for more interested in...
International Edition